Table 1.
Patient characteristics in relation to the tumorigenicity of engrafted tumors in a xenograft model
| Characteristic | Total patients (n=88) | Tumorigenicity |
||
|---|---|---|---|---|
| Yes (n=47) | No (n=41) | p-value | ||
| Age, median (range, yr) | 53 (27-82) | 54 (32-82) | 52 (27-72) | 0.460 |
| Preoperative CA-125 level (U/mL) | 1,527.2 (2-11,779) | 1,157.1 (2-8,189) | 1,951.5 (28-11,779) | 0.439 |
| Histology | ||||
| Serous | 54 (61.4) | 31 (66.0) | 23 (56.1) | 0.594 |
| Mucinous | 4 (4.5) | 3 (6.4) | 1 (2.4) | |
| Endometrioid | 11 (12.5) | 4 (8.5) | 7 (17.1) | |
| Clear cell | 12 (13.6) | 5 (10.6) | 7 (17.1) | |
| Carcinosarcoma | 3 (3.4) | 2 (4.3) | 1 (2.4) | |
| Squamous cell | 1 (1.1) | 1 (2.1) | 0 | |
| Unknown | 3 (3.4) | 1 (2.1) | 2 (4.9) | |
| FIGO stage | ||||
| I | 11 (12.5) | 6 (12.8) | 5 (12.2) | 0.831 |
| II | 4 (4.5) | 2 (4.3) | 2 (4.9) | |
| III | 52 (59.1) | 26 (55.3) | 26 (63.4) | |
| IV | 21 (23.9) | 13 (27.7) | 8 (19.5) | |
| High-grade tumor | 66 (75.0) | 39 (83.0) | 27 (65.9) | 0.054 |
| Lymphovascular invasion | 40 (45.5) | 27 (57.4) | 13 (31.7) | 0.016 |
| LN metastasis | 41 (46.6) | 24 (51.1) | 17 (41.5) | 0.368 |
| BRCA1/2 mutation | 14 (15.9) | 10 (21.3) | 4 (9.8) | 0.142 |
| Type of surgery | ||||
| Primary debulking | 64 (72.7) | 36 (76.6) | 28 (68.3) | 0.661 |
| Interval debulking | 24 (27.3) | 11 (23.4) | 13 (31.7) | |
| ASA physical status | ||||
| 1 | 13 (14.8) | 7 (14.9) | 6 (14.6) | 0.999 |
| 2 | 43 (48.9) | 23 (48.9) | 20 (48.8) | |
| 3 | 32 (36.4) | 17 (36.2) | 15 (36.6) | |
| Residual disease | ||||
| NGR | 50 (56.8) | 21 (44.7) | 29 (70.7) | 0.022 |
| < 1 cm | 26 (29.5) | 16 (34.0) | 10 (24.4) | |
| ≥ 1 cm | 12 (13.6) | 10 (21.3) | 2 (4.9) | |
Values are presented as number (%) unless otherwise indicated. CA-125, carbohydrate antigen 125; FIGO, The International Federation of Gynecology and Obstetrics; LN, lymph node; ASA, American Society of Anesthesiologists; NGR, no gross residual disease.